世界中医药
文章摘要
引用本文:罗丽华.化疗联合参麦注射液对晚期非小细胞肺癌患者细胞免疫及肿瘤恶性程度的影响[J].世界中医药,2017,(05):.  
化疗联合参麦注射液对晚期非小细胞肺癌患者细胞免疫及肿瘤恶性程度的影响
Effect of Chemotherapy Combined with Shenmai Injection on Cellular Immunity and Tumor Malignance of Advanced Non-small Cell Lung Cancer Patients
投稿时间:2017-03-24  
DOI:10.3969/j.issn.1673-7202.2017.05.034
中文关键词:  非小细胞肺癌  化疗  参麦注射液  细胞免疫  肿瘤标志物  疗效
English Keywords:Non-small cell lung cancer  Chemotherapy  Shenmai Injection  Cellular immunity  Tumor markers  Efficacy
基金项目:
作者单位
罗丽华 河北省秦皇岛市第三医院肿瘤科,秦皇岛,066000 
摘要点击次数: 1129
全文下载次数: 1439
中文摘要:
      目的:探讨化疗联合参麦注射液治疗晚期非小细胞肺癌(NSCLC)的临床疗效及对患者细胞免疫、肿瘤恶性程度的影响。方法:选取2011年5月至2016年2月秦皇岛市第三医院收治的NSCLC患者162例,随机分为观察组和对照组,每组81例。对照组患者给予单纯化疗治疗,观察组在对照组的基础上联合参麦注射液治疗。治疗6个月后统计2组临床疗效;检测并比较治疗前后2组患者血清炎性细胞因子水平及肿瘤标志分子水平;检测并比较治疗前后2组患者全血中T淋巴细胞亚群比例的变化;统计治疗期间2组不良反应。结果:治疗6个月后观察组缓解率为79.01%,显著高于对照组的50.62%(P<0.01);与治疗前比较,治疗后观察组患者血清IFN-γ、IL-2、TNF-α水平均明显升高,且显著高于对照组(P<0.05或P<0.01);观察组患者血清IL-6及IL-10水平均明显降低,且显著低于对照组(P<0.01);与治疗前比较,治疗后对照组CD4+比例及CD4+/CD8+均明显降低(P<0.01),而观察组CD8+比例明显降低,CD4+比例、NK细胞比例及CD4+/CD8+均明显升高(P<0.05或P<0.01),且2组间差异有统计学意义(P<0.05或P<0.01);与治疗前比较,治疗后2组血清CEA、CA125、CYFRA21-1、NSE及SCC-Ag水平均明显降低,且观察组显著低于对照组(P<0.01);与对照组比较,观察组患者恶心、呕吐,白细胞减少及血小板下降发生率明显降低(P<0.05或P<0.01)。结论:化疗联合参麦注射液可明显调节晚期NSCLC患者血清细胞因子水平,提高患者细胞免疫功能,并有效降低血清肿瘤标志物水平,降低肿瘤恶性程度,疗效显著优于化疗单用,同时其也可有效降低患者不良反应发生率,具有较高的安全性。
English Summary:
      To investigate the clinical efficacy of chemotherapy combined with Shenmai injection in the treatment of advanced non-small cell lung cancer (NSCLC) and its effect on cellular immunity and tumor malignant degree of patients. Methods: A total number of 162 patients with NSCLC admitted in the hospital from May 2011 to February 2016, and were randomly divided into control group and observation group, with 81 cases in each group. The patients in the control group were treated with chemotherapy, while patients in the observation group were additionally treated with Shenmai Injection. The clinical efficacy of the two groups was evaluated after 6-month treatment. The levels of serum inflammatory cytokines and tumor markers were measured and compared between the two groups before and after the treatment. Changes of T lymphocyte subsets in the whole blood of the two groups were detected and compared before and after treatment. Adverse reactions during the treatment were observed. Results: After 6-month treatment, the remission rate was 79.01% in the observation group, which was significantly higher than that of 50.62% in the control group (P<0.01). The levels of serum IFN-γ, IL-2 and TNF-α in the observation group were significantly higher than those in the control group (P<0.05 or P<0.01). The levels of IL-6 and IL-10 in the observation group were significantly lower than those in the control group (P<0.05 or P<0.01). The proportion of CD4+ and CD4+/CD8+ in the control group were significantly lower (P<0.01), while the proportion of CD8+ in the observation group significantly decreased.CD4+ ratio, NK cell ratio and CD4+/CD8+ significantly increased (P<0.05 or P<0.01), and there was significant difference between the two groups after the treatment (P<0.05 or P<0.01).The levels of serum CEA, CA125, CYFRA21-1, NSE and SCC-Ag in the two groups were significantly lower and the observation group was significantly lower than the control group after the treatment (P<0.01). The incidence of nausea, vomiting, leukopenia and thrombocytopenia was significantly lower, compared with the control group (P<0.05; P<0.01). Conclusion: Chemotherapy combined with Shenmai injection may significantly regulate the serum cytokine levels in patients with advanced NSCLC, improve the cellular immune function, effectively reduce serum tumor marker level and reduce tumor malignancy. The effect is significantly better than chemotherapy and it may effectively reduce the incidence of adverse reactions with high safety.
查看全文  查看/发表评论  下载PDF阅读器